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Ingenol Mebutate Field-Directed Treatment of
UVB-Damaged Skin Reduces Lesion Formation and
Removes Mutant p53 Patches
Sarah-Jane Cozzi1,2,6, Steven M. Ogbourne2,7, Cini James1, Heggert G. Rebel3, Frank R. de Gruijl3,
Blake Ferguson1, Joy Gardner1, Thuy T. Lee1, Thibaut Larcher4 and Andreas Suhrbier1,5
Skin cancer is the most prevalent cancer worldwide and is primarily caused by chronic UV exposure. Here, we
describe the topical field-directed treatment of SKH1/hr mice with UVB-damaged skin with ingenol mebutate, a
new topical drug shown to be effective for the treatment of actinic keratosis (AK). Application of 0.05% ingenol
mebutate gel to photo-damaged skin resulted in a E70% reduction in the number of skin lesions that
subsequently emerged compared with placebo treatment. Ingenol mebutate treatment also reduced the
number of mutant p53 keratinocyte patches by E70%. The treatment resulted in epidermal cell death, acute
inflammation, recruitment of neutrophils, hemorrhage, and eschar formation, all of which resolved over several
weeks. Ingenol mebutate field-directed treatment might thus find utility in the removal of subclinical
precancerous cells from UV-damaged skin. Field-directed treatment may be particularly suitable for patients
who have AKs surrounded by UV-damaged skin.
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INTRODUCTION
Non-melanoma skin cancers (NMSCs) are the most common
cancers worldwide, with the incidence increasing by 3–8%
annually (Madan et al., 2010; Rogers et al., 2010). The direct
cost of treating NMSC in the USA in 2004 was estimated to
be US$ 1.4 billion (The Lewin Group, 2005) with over 2
million patients treated in 2006 (American Cancer Society,
2010). UV radiation, usually from sunlight, is the most
important risk factor for skin cancer; however, despite
increased public awareness of the dangers of sun exposure,
the incidence continues to rise (Madan et al., 2010; Rogers
et al., 2010). The reasons for this increase likely include
better detection of the disease, the aging population (Madan
et al., 2010), and increasing UV radiation due to ozone
depletion (Norval et al., 2007; Chang et al., 2010). Sunlight,
particularly UVB, is able to act both as a tumor initiator and a
tumor promoter, with UVB able to damage DNA directly
(Ziegler et al., 1994; Rass and Reichrath, 2008; Madan et al.,
2010).
Mutations of the p53 tumor suppressor gene are particu-
larly common in skin cancers, and are considered to be an
important early event in skin cancer oncogenesis (Rebel
et al., 2005; Benjamin et al., 2008; de Gruijl and Rebel,
2008). Chronic UV exposure results in the accumulation in
the skin of histologically detectable ‘‘p53 patches’’, which
are clonal outgrowths of keratinocytes with elevated nuclear
expression of mutated p53 (Berg et al., 1996; Rebel et al.,
2001, 2005). A small number of these mutant p53 patches
may progress to actinic keratosis (AK; Einspahr et al., 1999)
and ultimately NMSC, with further mutations, UV-induced
immunosuppression, and/or human papilloma virus infection
contributing to cancer formation (Hart et al., 2001; Rebel
et al., 2005; Byrne et al., 2008; Murphy, 2009; Madan et al.,
2010). Although a number of factors can influence the
propensity of these mutated keratinocytes to develop into
NMSC (Madan et al., 2010), these UV-mutated cells appear
to be a prerequisite for the development of most NMSC
(Ananthaswamy et al., 1998; Benjamin et al., 2008; Rass and
Reichrath, 2008). Consistent with this view is that prophy-
lactic treatments, such as sunscreen application, that reduce
the number of p53 patches, also reduce the number of skin
cancers that subsequently develop (Ananthaswamy et al.,
2002; Conney et al., 2008).
Ingenol mebutate is currently being developed as a new
topical antineoplastic drug, which has been shown to be
effective and well tolerated in the treatment of AKs and
NMSC (Anderson et al., 2009; Siller et al., 2009, 2010).
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Preclinical studies have shown that the mechanism of action
involves the induction of primary necrosis in tumor cells,
disruption of tumor vasculature, transient inflammation, and
recruitment of neutrophils, with treatment resulting in a
favorable cosmetic outcome (Challacombe et al., 2006;
Ogbourne et al., 2007; Li et al., 2010). Here we show, using
the hairless SKH-1/hr mouse model, that field-directed
treatment (Berman et al., 2009; Jorizzo et al., 2010; Feldman
and Fleischer, 2011) of precancerous chronically UVB-
irradiated skin with ingenol mebutate significantly
reduced the number of skin lesions that subsequently
developed. Ingenol mebutate treatment also significantly
reduced the number of mutant p53 patches present in the
skin. This study thus illustrates that ingenol mebutate may
find utility for the field-directed treatment of UV-damaged
skin to reduce the emergence of AKs and NMSC. Such
treatment may be particularly suitable for patients
with multiple or recurring AKs (Berman et al., 2009; Jorizzo
et al., 2010; Feldman and Fleischer, 2011) and/or patients
who are at high risk of developing NMSC (Marcil and Stern,
2000).
RESULTS
Field-directed treatment of UVB-damaged skin with 0.05%
ingenol mebutate gel reduced the emergence of UVB-induced
skin lesions
SKH1/hr mice were exposed to 1.25 minimal erythemal dose
UVB three times per week over 10–11 weeks for a total of 30
doses. The day after the final irradiation dose, the dorsum of
each mice was tattooed with rectangles to demarcate the
treatment areas. Mice were randomly assigned into three
groups. The first group was treated topically, daily for 2 days
with B100ml of 0.05% ingenol mebutate gel within the
tattooed areas (Figure 1a, Ing. meb.). The second group was
treated with placebo gel within the tattooed areas (Figure 1a,
placebo). The third group remained untreated (Figure 1a,
control). The mice were examined weekly for 21 weeks for
the development of UV-induced skin lesions. Ingenol
mebutate gel field–directed treatment resulted in a significant
60–70% reduction in the number of skin lesions per cm2
within the treatment areas that emerged over time compared
with placebo treatment and the controls (Figure 1a). At all
time points after 12 weeks, the ingenol mebutate group
showed significantly fewer lesions than the other two groups
(Po0.05, Mann–Whitney U-test). As the treatment areas
encompassed much of the UVB-damaged skin of the mouse,
this also resulted in aE70% reduction in the total number of
lesions per mouse (Figure 1b). The slight increase in the
number of lesions seen with placebo gel–treated group
compared with controls (Figure 1a and b) may be because
of mice scratching the treatment site, with skin wounding
or abrasion known to promote epidermal carcinogenesis
(Argyris, 1985).
The number of skin lesions outside the treatment areas was
not significantly affected (Figure 1c), suggesting that the
ingenol mebutate treatment did not induce effective systemic
immunity against keratinocytes overexpressing mutated p53
(Le et al., 2009). This is consistent with the view that mutant
p53 patches are not under immune control (Remenyik et al.,
2003; de Graaf et al., 2008).
To analyze the effect of 0.05% ingenol mebutate gel
treatment on tumor burden, Kaplan–Meier curves were
generated by analyzing the total lesion area within the
treatment area (Figure 1d) and the total dorsal lesion area
per mouse over time (Figure 1e). For both analyses, an event
was assigned when the total lesion area reached 70mm2.
Both analyses showed that 0.05% ingenol mebutate gel
treatment led to a significant reduction in the number of
mice that had a total lesion area of 70mm2 when compared
with placebo gel–treated or control mice (Figure 1d and e;
ingenol mebutate vs placebo; log rank statistic; Po0.001
and Po0.002, respectively). Forty-five percent of mice
treated with ingenol mebutate actually had no lesions
within the treatment areas, whereas placebo and control
groups all had at least five lesions at week 21 (data not
shown). Thus, both the number of lesions and the lesion
burden (as determined by total lesion area) were signifi-
cantly reduced by field-directed treatment with 0.05%
ingenol mebutate gel.
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Figure 1. Development of UVB-induced lesions after treatment of UVB-
irradiated skin with ingenol mebutate. After 30 doses of UVB, SKH1/hr mice
were treated daily for 2 days with 0.05% ingenol mebutate gel (Ing. meb.) or
placebo gel (Placebo) or were left untreated (Control). (a) The mean number
of dorsal lesions per mouse per cm2 within the treatment area over time;
n¼ the number of mice. (b) The mean number of dorsal lesions per mouse
over time. (c) The mean number of dorsal lesions outside the tattooed areas
per mouse. (d) Kaplan–Meier curves showing the percentage of mice with a
total lesion area within the treatment area of o70mm2. (e) Kaplan–Meier
curves showing the percentage of mice with a total lesion area of o70mm2;
(see Supplemental material online for mouse number details).
1264 Journal of Investigative Dermatology (2012), Volume 132
S-J Cozzi et al.
Ingenol Mebutate Field-Directed Treatment of UVB-Damaged Skin
Growth rates, size distribution, and histology of lesions
emerging after ingenol mebutate treatment were no different
from those in control animals
To illustrate that ingenol mebutate treatment did not select for
the emergence of more aggressive lesions, the growth rates of
individual lesions within the treatment areas were examined
for each group. The area of each individual lesion was plotted
over time with week 0 assigned as the week before an
individual lesion was identified (irrespective of the time of
emergence of the lesion relative to the time of treatment;
Figure 2a). No lesion in the ingenol mebutate–treated group
grew faster than any lesion in the placebo group (Figure 2a).
Five placebo mice with the large tumors (Figure 2a) were
euthanized before week 21 because of an excessive overall
tumor burden. The two larger tumors in the ingenol mebutate
group (Figure 2a) grew larger only because an excessive
overall tumor burden was not reached before week 21.
Analysis of the mean lesion growth rates also showed that
there was no significant difference between control, placebo,
and ingenol mebutate gel–treated mice (Figure 2b; the error
bars for the mean area of lesions in the ingenol mebutate
treatment group are larger as the number of lesions was
lower).
The size distribution of lesions within the treatment area
was analyzed to determine whether the lesions that remained
21 weeks after ingenol mebutate treatment showed any
changes in size profile. Although more lesions were present
in control and placebo gel–treated mice compared with
ingenol mebutate–treated mice, a similar lesion size distribu-
tion profile was present in all three groups (Figure 2c).
Histological analysis of lesions from all three groups
showed that lesions were of epidermal origin and resembled
the classical picture described previously for lesions in this
model (Kligman and Kligman, 1981). No differences in the
histology were observed for lesions that emerged after
ingenol mebutate treatment and those in the placebo or
control groups (data not shown).
These data illustrate that treatment with ingenol mebutate
gel did not result in, or select for, the emergence of more
aggressive, or larger, or histologically distinct tumors.
Skin appearance after ingenol mebutate treatment of
UVB-damaged and normal skin
Treatment with 0.05% ingenol mebutate gel of chronically
UVB-irradiated skin caused reddening of the skin, visible
within 1 hour of treatment, with erythema increasing with
time (Figure 3a). By 48 hours (24 hours after the second dose),
eschar formation had begun and by days 5–9 it had
encompassed the treatment area. The eschar resolved after
3–4 weeks, leaving a pink treatment area (Figure 3a), which
lightened over subsequent weeks.
Treatment of normal skin (with no UV exposure) with
0.05% ingenol mebutate (n¼ 5 mice) appeared to result in
less reddening of the skin at 24–48 hours, although eschar
formation and skin contraction appeared to be similar (Figure
3b).
At 21 weeks after ingenol mebutate treatment of UVB-
damaged skin, the number of lesions within the treatment
areas was clearly lower, when compared with placebo and
control mice (Figure 3c). The mean skin area within the
ingenol mebutate treatment area (demarcated by tattoo) had
also reduced byE3-fold (Figure 3c); this was also apparent at
day 29 (Figure 3a and b). This contraction resulted in skin
surrounding the treatment site being pulled toward the
treatment site (data not shown). At week 21, after ingenol
mebutate treatment, the treated skin felt and appeared largely
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Figure 2. Growth and size profiles of UVB-induced skin lesions after ingenol
mebutate (Ing. meb.) treatment. (a) Growth curves of individual lesions
arising in ingenol mebutate- and placebo-treated mice, and control mice.
The size of individual lesions within the tattoo areas from the mice described
in Figure 1 were measured over time, with week 0 designated as the
week before an individual lesion became apparent. (b) The mean size of the
lesions shown in a over time. (c) The size profile of the lesions within the
treatment areas in ingenol mebutate- and placebo-treated mice, and control
mice at 21 weeks post treatment initiation. Lesions were sorted from the
smallest to the largest area, with each lesion represented by one data point.
The large tumor in a (Ing meb.) was not included, as at week 21 it had
coalesced with another tumor, making size determination difficult.
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normal, although slightly darker pink irregular markings
remained within the treatment areas (Figure 3c, ingenol
mebutate).
Skin histology after ingenol mebutate treatment of
UVB-damaged skin
Histology of placebo-treated skin showed the expected
epidermal thickening that arises after chronic UVB irradiation
(Chaquour et al., 1995) when comparing normal skin (Figure
4a) with placebo (Figure 4b). Six hours after the first treatment
with 0.05% ingenol mebutate gel, disruption of the basal
epidermis was evident when comparing placebo (Figure 4b)
with ingenol mebutate (Figure 4c). Higher magnifications
showed ballooning degeneration of basal keratinocytes when
comparing placebo (Figure 4f) with ingenol mebutate (Figure
4g). By 24 hours post ingenol mebutate treatment, extensive
cellular infiltrates (predominant neutrophils) could be seen in
the dermis, and extensive areas of epidermal keratinocytes
showed hyper eosinophilic staining (Figure 4d). (This loss of
blue basophilic hematoxylin staining in the cytoplasm is
usually associated with the loss of ribosomal RNA with a
consolidation of cytoplasmic components as the cell col-
lapses.) Higher magnification of the epidermis showed
keratinocytes with consistent pyknotic nuclei and widespread
coagulative necrosis (Figure 4h). These features are consistent
with acute primary necrosis of keratinocytes (Haschek et al.,
2009), and illustrated that ingenol mebutate treatment had
killed most of the epidermal keratinocytes. At 48 hours
(24 hours after second treatment), the epidermis was absent
in many places and was replaced by an eschar (Figure 4e).
Areas containing extensive cellular infiltrates were evident
throughout the dermis (Figure 4e), and at higher magnifica-
tions these areas showed pyodermatitis, predominantly
composed of red blood cells and degenerating neutrophils
(Figure 4i), consistent with previous observations (Challa-
combe et al., 2006). Healthy (hematoxylin staining) kerati-
nocytes were clearly present in hair follicles and appeared, in
several places, to be reconstituting the epidermis (Figure 4e
and j). Strong Ki67 staining was apparent in the hair follicles
and the epidermis at this time (Figure 4k), illustrating
0 Hours
48 Hours Day 9
Ingenol mebutate Placebo Control
Day 16 Day 29 48 Hours Day 9 Day 16 Day 29
1 Hour 6 Hours 24 Hours 0 Hours 1 Hour 6 Hours 24 Hours
Figure 3. Skin appearance after ingenol mebutate treatment. (a) Photographs of UVB-irradiated skin within the tattooed areas at the indicated times after
treatment initiation with 0.05% ingenol mebutate gel (48 hours represents 24 hours after the second treatment). (b) As in a, except that normal skin was treated.
(c) Photographs of representative mice from ingenol mebutate and placebo treatment, and control groups taken 21 weeks post treatment initiation.
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keratinocyte replication and suggesting keratinocyte emer-
gence from hair follicles leading to re-epithelialization of the
skin (Lau et al., 2009). Ki67 staining was less apparent in
placebo gel–treated skin (Figure 4l) and control staining of
ingenol mebutate–treated skin was negative (Figure 4m). At
21 weeks post treatment, the lesion-free epidermis in ingenol
mebutate–treated skin was indistinguishable by hematoxylin
and eosin staining from normal skin (data not shown).
Toluidine blue staining of skin from naive (Figure 4n) and
placebo gel–treated (Figure 4o) mice showed the increased
number of dermal mast cells usually found in chronically UV-
irradiated skin in mice and humans (Kligman and Murphy,
1996; Gonzalez et al., 1999; Bosset et al., 2003). Six hours
post ingenol mebutate treatment, the mast cell granules,
which are stained pink–purple by toluidine blue, appeared
more dispersed, suggesting that the mast cells were either
dying and/or degranulating (Figure 4p). At 24 hours, few
toluidine blue–staining cells could be seen (Figure 4q). At
48 hours after treatment initiation, toluidine blue–staining
cells could again be seen; however, the dominant feature was
the extensive red/brown pigment throughout the dermis,
indicating widespread hemorrhage (Figure 4r). At 21 weeks
post treatment, the number of dermal toluidine blue–staining
cells was similar in naive, placebo, and ingenol mebutate–-
treated groups, and no signs of hemorrhage were evident
(data not shown).
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Figure 4. Histology of UVB-irradiated skin treated with 0.05% ingenol mebutate (Ing. meb.) gel. (a–i) Hematoxylin and eosin staining. (a) The skin of naive
mice. (b) The skin of mice irradiated with UVB as described above and treated with placebo gel. (c) UVB-irradiated skin 6 hours after treatment with 0.05%
ingenol mebutate gel. (d) UVB-irradiated skin 24 hours after treatment with 0.05% Ing. meb gel. (e) UVB-irradiated skin 48 hours after the first treatment with
0.05% ingenol mebutate gel. (f) High magnification of skin treated as in b. (g) High magnification of skin treated as in c. (h) High magnification of skin treated as
in d. (i, j) High magnifications of dermis and epidermis of mice treated as in e. (k) Ki67 staining of skin treated as in e. (l) Ki67 staining of skin treated as in b.
(m) Control antibody staining of skin treated as in e. (n–r) Toluidine blue staining of skin treated as in a–e; insets for o and p show high magnifications of
individual toluidine blue–staining cells. (s–w) Treatment of normal skin with 0.05% ingenol mebutate; (s, t) 24 hours after treatment, (u–w) 48 h after treatment.
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Skin histology after ingenol mebutate treatment of normal skin
Treatment of normal skin with 0.05% ingenol mebutate
resulted in similar, although delayed, changes to the
epidermis compared with treatment of UV-irradiated skin.
Ballooning degeneration of keratinocytes was observed at
24 hours (Figure 4s and t), and extensive coagulative necrosis
and hyper eosinophilic staining were not seen until 48 hours
after treatment initiation (Figure 4u and v). In addition, the
extent of hemorrhage and neutrophil infiltration at 48 h
(Figure 4w) was less than that seen for UV-irradiated skin.
These histological findings are consistent with the reduced
reaction seen on normal skin (Figure 3b). However, the
similar eschar formation (Figure 3b) is consistent with the
observation that in both UV-irradiated (Figure 4h) and normal
skin (Figure 4v) epidermal keratinocytes were killed by the
ingenol mebutate treatment.
Field-directed treatment of UVB-irradiated skin with ingenol
mebutate reduced the number of mutant p53 patches
Chronic UVB irradiation results in the accumulation of
mutant p53 epidermal patches, which are believed to be
prerequisite precursors of UVB-induced skin lesions (Berg
et al., 1996; Rebel et al., 2001, 2005). To ascertain whether
post-UVB ingenol mebutate field-directed treatment affects
p53 patch numbers, SKH1/hr mice were exposed to 1.25
minimal erythemal dose three times a week for 11–12 weeks.
Mice were then divided into three groups, one was treated on
the dorsum with 0.05% ingenol mebutate gel, one was
treated with placebo gel, with the third group left untreated
(control). After the healing process was complete in the
ingenol mebutate treatment group, the mice from all the
groups were euthanized and the epidermis within the
treatment areas were analyzed for the presence of p53
patches using immunohistochemistry. An example of a
typical mutant p53 patch at low and high magnifications is
shown in Figure 5a.
Enumeration of the number of p53 patches showed that
chronically irradiated skin in the absence of treatment had
89±10.8 (SE) p53 patches per cm2 (Figure 5b, control),
whereas unirradiated skin from the underbelly of the same
mice showed no detectable p53 patches (data not shown).
Placebo gel treatment had no significant effect on p53 patch
density (Figure 5b, placebo) with 103.3±18.1 (SE) p53
patches per cm2 (Figure 5b, placebo). In contrast, treatment
with 0.05% ingenol mebutate gel resulted in a significant
E70% reduction (P¼0.002) in the number of p53 patches
per cm2 (26.8±6.3 SE) within the treatment areas (Figure 5b,
Ing. meb.). A parallel experiment using a 0.01% ingenol
mebutate had no significant effect on the number of p53
patches (data not shown).
DISCUSSION
Herein, we show that field-directed treatment of chronically
UVB-irradiated skin with 0.05% ingenol mebutate gel
resulted in a E70% reduction in the number of skin lesions
that emerged over time. Ingenol mebutate field-directed
treatment caused loss of the epidermis, which appeared to be
followed by rapid re-epithelization from hair follicles. The
treatment also caused a significant reduction in the number of
mutant p53 patches in the newly formed epidermis, suggest-
ing removal of replication-competent mutant p53–expressing
keratinocytes that give rise to these patches. These experi-
ments highlight the potential for the use of ingenol mebutate
as a field-directed treatment for chronically UVB-damaged
skin to prevent the development of AKs and NMSC.
Ingenol mebutate field-directed treatment may be parti-
cularly suitable for individuals who have a history of UV
exposure and are at high risk of developing further NMSC
(Jonason et al., 1996; Marcil and Stern, 2000; Bailey et al.,
2010). In humans, chronic UV exposure results in the
accumulation of a substantial burden of premalignant
keratinocytes (detectable as p53 patches) from which AKs
(Einspahr et al., 1999) and NMSC are able to develop
(Jonason et al., 1996; Feldman and Fleischer, 2011). An
individual’s risk of developing NMSC depends on a number
of environmental and genetic factors (Madan et al., 2010).
However, meta-analysis has shown that patients who develop
one NMSC have at least 10-fold higher probability of
developing another NMSC within 3 years when compared
with the general population (Marcil and Stern, 2000). Such
patients currently have limited treatment options to reduce
their NMSC risk (Bailey et al., 2010) and currently rely on
continued monitoring for, and treatment of, newly emerging
AKs and NMSC (Cohen, 2010). A recent development is the
notion of field-directed treatment, which seeks to remove
both AKs and any surrounding subclinical lesions (Feldman
and Fleischer, 2011). A phase III human trial of 0.05%
ingenol mebutate treatment of 25 cm2 areas containing AKs
was recently completed and showed a 69% reduction in AK
lesion count (Swanson, 2011). The current paper provides the
first evidence that such field-directed treatments may also
reduce the subsequent emergence of AKs and squamous cell
carcinomas from the treatment area by removing keratino-
cytes with malignant potential.
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Figure 5. Ingenol mebutate (Ing. meb.) field-directed treatment reduced the
number of mutant p53 patches. After 30 doses of UVB, SKH1/hr mice were
left untreated (Control), or were treated with placebo or 0.05% ingenol
mebutate (days 0 and 1). Four or five weeks after treatment, the epidermis was
analyzed for p53 patches by immunohistochemistry. (a) Representative
photographs of a p53 patch in a control animal (arrows). The epidermis was
mounted basal side up and viewed from the top. White arrowheads show hair
follicles. Bars¼100 mm. (b) The number of p53 patches per cm2 in control
UVB-irradiated untreated mice (n¼20), and UVB-irradiated mice treated
with placebo gel (Placebo; n¼ 17) or Ing. meb. (n¼22). The data shown were
generated in two independent experiments; each individual experiment
showed significant differences (data not shown). Bars represent the mean
(statistical analysis by Mann–Whitney U-test).
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Field-directed treatments of 25 cm2 (Swanson, 2011) and
up to 100 cm2 areas (Schmieder, 2010) with ingenol
mebutate in human trials were generally well tolerated.
Importantly, skin contractions, like those seen in the mice
(Figure 3), were not observed, suggesting that dermal
hemorrhage and disruption is less pronounced in humans.
Mouse and human skin differ in a number of aspects, and
thus responses to ingenol mebutate are likely to differ.
Whether the pronounced hemorrhage, erythema, and eschar
formation seen in the mouse are required for the removal of
mutant p53 patches in humans is unclear. However, clinical
trial experience (Anderson et al., 2009; Siller et al., 2009;
Swanson, 2011) suggests that effective removal of abnormal
epidermal keratinocytes (in the form of AKs) can be achieved
without such robust responses.
The treatment of normal skin (that had received no UVB
irradiation) with 0.05% ingenol mebutate resulted in less
erythema at 24–48 hours. The reason for this is unclear.
Normal skin may be less permeable to ingenol mebutate than
UVB-damaged skin (Wang et al., 2010). Expression of the
epidermal multidrug transporter (Li et al., 2010) may be
higher in UV-irradiated skin (Uchiumi et al., 1993).
Degranulation of mast cells, which are elevated in chroni-
cally UVB-irradiated skin, may also be involved (Chai et al.,
2011).
Mast cells are believed to have important roles in UV-
induced immunosuppression and the development of NMSC
(Andreu et al., 2010; Chacon-Salinas et al., 2011). Whether
the ingenol mebutate–induced degranulation or the removal
of mast cells contributed to the reduction in skin lesion
development (Figure 1) remains unclear. However, the effect
appeared to be transient with mast cell granule staining
returning at 48 hours post treatment initiation (Figure 4r).
Even if ingenol mebutate–induced degranulation did transi-
ently reduce mast cell–mediated immunosuppression (de
Vries et al., 2009), the effect on subsequent lesion emergence
in the current model would likely be minimal as precancer-
ous keratinocytes are believed not to be controlled by the
immune system (Remenyik et al., 2003; de Graaf et al.,
2008).
Recently, chemical peels were also shown to reduce p53
patch numbers and lesion formation in chronically UVB-
irradiated mice (Abdel-Daim et al., 2010). However, this
involved 10 treatments (1 treatment every 2 weeks), whereas
a similar effect was achieved herein with only two ingenol
mebutate treatments (once daily for 2 days). In addition,
chemical peel treatments continued while lesions and tumors
were developing (Abdel-Daim et al., 2010), a scenario
unlikely to be countenanced in humans. The chemical peel
strategy did, however, result in reductions in lesions
developing outside the treatment areas (Abdel-Daim et al.,
2010), something that was not observed for ingenol mebutate
field-directed treatment (Figure 1c). Treatment of lesions with
chemical peels may result in the production of systemic
antitumor immunity that can regresses distant lesions. We
have shown, for instance, that treatment of tumors with
ingenol mebutate results in the induction of anticancer CD8
T-cell immunity, which was capable of regressing distant
tumors (Le et al., 2009). Herein, ingenol mebutate field-
directed treatment was applied several weeks before skin
lesions were visible, therefore significant induction of
antitumor immunity is unlikely to have occurred. The ingenol
mebutate field-directed treatment described herein may
expose the immune system to antigens present in p53
patches. However, several groups have shown that p53
patches are not regressed by immune-based mechanisms
(Remenyik et al., 2003; de Graaf et al., 2008), therefore such
immunity, even if induced, would have limited effect on p53
patches and subsequent lesion development.
Imiquimod has also been used to reduce p53 expression in
UV-damaged skin in humans, although the drug was applied
three times a week for 4 weeks and the implications for the
subsequent development of NMSC and AKs development
was not reported (Smith et al., 2007). Oral retinoids have also
been reported as being effective in reducing NMSC in high-
risk patients. However, treatment may need to be lifelong and
retinoids have the potential to produce adverse effects
(Hardin and Mydlarski, 2010; Marquez et al., 2010). Herein,
we show that only two treatments over 2 days with ingenol
mebutate were sufficient to reduce mutant p53 patch density
and lesion formation.
MATERIALS AND METHODS
The SKH1/hr model
Outbred SKH1/hr mice were obtained from Charles River Labora-
tories (Wilmington, NC) and a breeding colony for outbred SKH1/hr
mice was established at Queensland Institute of Medical Research
(QIMR). Male SKH1 mice were used for this study. To prevent any
fighting and injury (which promotes tumors), two mice were kept per
cage, separated by a physical barrier. All animal experiments were
approved by the QIMR Animal Ethics Committee.
UVB irradiation
Outbred SKH1/hr mice were irradiated three times per week for
10–11 weeks with 1.25 times the minimal erythemal dose of UVB at
each exposure (Rebel et al., 2001). For details see Supplementary
material online.
Ingenol mebutate. Isopropanol-based gel containing ingenol
mebutate (495% pure) was supplied by Peplin Ltd (Brisbane,
Queensland, Australia).
Immunohistochemistry and histology
One to three days after discontinuation of UVB irradiation, a
E4 cm2 dorsal area was treated topically daily for 2 days with 40 ml
of 0.05% (w/v) ingenol mebutate gel or placebo gel. The treatment
area was demarcated by a tattoo. An untreated group served as an
additional control. Once the treated area had healed (4–5 weeks),
the mice were euthanized for analysis of mutant p53 patches. The
treated skin areas were surgically excised and the epidermis was
stained with a mutant-specific anti-p53 antibody. For details see
Supplemental material online.
For Ki67 staining, paraffin sections were treated with Target
Retrieval Solution of pH6 (Dako Australia, Noble Park, Victoria,
Australia) and Ki67 stained with rat anti-mouse Ki67 (TEC-3; Dako).
Detection was by horseradish peroxidase as above.
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For histological studies, samples were fixed in 10% formalin and
processed for paraffin embedding at the indicated times after ingenol
mebutate treatment. Paraffin sections were stained with hematoxylin
and eosin or toluidine blue using standard protocols.
Ingenol mebutate treatment and lesion monitoring
One to three days after discontinuation of UVB irradiation,B10 cm2
rectangular areas (one per mouse) located centrally on the dorsa and
previously demarcated by tattoos were treated topically, daily for 2
days with 100 ml of 0.05% ingenol mebutate gel or 100ml of placebo
gel. An untreated group served as an additional control. The mice
were monitored weekly for the development of lesions both within
and outside the treatment areas. Lesions arising on the tattooed lines
were considered outside the treatment area. The number and size of
lesions were monitored over time. All visible lesions were counted.
Lesions o2mm were mostly AKs, whereas lesions 43mm were
mostly squamous cell carcinomas (de Gruijl, 2008). The mice were
euthanized at the end of the study or earlier in cases where total
lesion area was excessive or other welfare issues required
euthanasia.
Data analysis
Statistical analysis was carried out using Graphpad Prism version
5.03. (Graphpad Software, San Diego, CA, http://www.graphpad.
com) or SPSS for Windows (version 15.0, 2007; SPSS, Chicago, IL).
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